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ABSTRACT 
Diabetes mellitus is defined as a state in which homeostasis of carbohydrate and lipid metabolism is improperly regulated by insulin. This results 
primarily in elevated fasting and postprandial blood glucose levels. If this imbalanced homeostasis dose not returns to normalcy and continues 
for a protracted period of time, it leads to hyperglycemia, which in due course turns into a syndrome called diabetes mellitus. Several animal 
models have been developed for studying diabetes mellitus or testing anti-diabetic agents. These models include chemical, surgical 
(pancreatectomy) and genetic manipulations in several animal species to induce diabetes mellitus. The diabetogenic drugs used include: Alloxan 
monohydrate, Streptozotocin with or without nicotinamide, Ferric nitrilotriacetate, Ditizona and Anti-insulin serum. The selection of these 
models to use for investigating the antidiabetic properties of a new compound may be a very difficult task especially for young researchers. The 
aim of the present review is give a brief idea about various experimental models developed for studying diabetes mellitus, assess the merits and 
demerits of each model and highlight the precautions needed to avoid erroneous results during the applications of these models.  
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INTRODUCTION 
Diabetes mellitus is defined as a state in which homeostasis 
of carbohydrate and lipid metabolism is improperly 
regulated by insulin. This results primarily in elevated 
fasting and postprandial blood glucose levels. If this 
imbalanced homeostasis dose not returns to normalcy and 
continues for a protracted period of time, it leads to 
hyperglycemia, which in due course turns into a syndrome 
called diabetes mellitus 1. The long term effects of diabetes 
mellitus include progressive development of the specific 
complications of retinopathy with potential blindness, 
nephropathy that may lead to renal failure, and/or 
neuropathy with risk of foot ulcers, amputation and features 
of autonomic dysfunction, including sexual dysfunction. 
People with diabetes are at increased risk of cardiovascular, 
peripheral vascular and cerebrovascular disease 2. There are 
two main categories of this disease - type 1 (insulin 
dependent diabetes mellitus, IDDM) and type 2 (non insulin 
dependent diabetes mellitus, NIDDM). Type 1 diabetes is 
typically a disease of juvenile onset and is associated with 
insulin deficiency, usually resulting from autoimmune 
destruction of pancreatic beta cells. Type 1 diabetic patients 
are prone to develop ketoacidosis and require insulin 
therapy to control their hyperglycemia. Type 2 diabetes is 
typically a disease of adult onset (although it is becoming 
increasingly recognized in children) and is caused by a 
combination of defective insulin secretion with reduced 
insulin sensitivity of the tissues. An increase in body fat is 
generally associated with an increase in risk of metabolic 
diseases such as type 2 diabetes mellitus, hypertension and 
dyslipidemia 3. This impaired glucose tolerance is usually 
associated with obesity and physical inactivity. Hyper-
glycemia in type 2 diabetic patients can be often managed 
using a combination of dietary modification and oral 
hypoglycemic drugs. It has become increasingly recognized 
that there are some diabetic patients who develop diabetes 
as adults (usually older than 30 years of age), who are 
initially diagnosed as having type 2 diabetes but who are not 
overweight and who also show evidence of circulating 
autoantibodies. These patients are often managed initially 
using oral hypoglycemic drugs, but they usually progress to 
insulin therapy. This form of diabetes has now been 
classified as Latent Autoimmune Diabetes of Adults (LADA), 
sometimes referred to as type 1.5 diabetes. Juvenile onset 
type 1 diabetes appears to result from an overwhelming auto 
-immune response against pancreatic beta cells that rapidly 
leads to their total destruction. In contrast, LADA seems to 
result from a more slowly progressive autoimmune process 
and it takes several years before the beta cell mass has been 
reduced to an extent whereby normoglycemia cannot be 
maintained and clinical signs of diabetes become apparent 4. 
Gestational diabetes mellitus (GDM) is defined as any degree 
of glucose intolerance with the onset or first recognition 
during pregnancy. The definition applies whether insulin or 
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only diet modification is used for treatment and whether or 
not the condition persists after pregnancy. It does not 
exclude the possibility that unrecognized glucose intolerance 
may have antedated or begun concomitantly with pregnancy. 
Approximately 7 per cent of all pregnancies are complicated 
by GDM, resulting in more than 200,000 cases annually. The 
prevalence may range from 1 to 14 per cent of all 
pregnancies, depending on the population studies and the 
diagnostic tests employed. Off springs of women with GDM 
are at an increased risk of obesity, glucose intolerance and 
diabetes in late adolescence and young childhood. Risk 
assessment for GDM should be undertaken at the first 
prenatal visit. Women with clinical characteristics consistent 
with high risk of GDM (marked obesity, personal history of 
diabetes) should undergo glucose testing. Women with GDM 
represent a high risk group for cardiovascular disease that 
can be identified years before the development of adverse 
events with the incidence of type 2 diabetes increasing at 
epidemic proportions 5. 
Animal Models for Diabetes Mellitus 6 
The currently existing animal models include: 
Chemically Induced Diabetes: 
Chemically induced Type-I diabetes is the most commonly 
used animal model of diabetes. Chemical agents which 
produce diabetes can be classified into three categories, and 
include agents that: 
 Specifically damage B-cell; 
 Cause temporary inhibition of insulin production and or 
secretion, and 
  Diminish the metabolic efficacy of insulin in target 
tissues.  
In general, chemicals in the first category are of interest as 
they reproduce lesions resembling IDDM 6.  
1. Alloxan-lnduced Diabetes  
Alloxan, a cyclic urea analogue, was the first agent in this 
category, which was reported to produce permanent 
diabetes in animals.  
How Alloxan induce diabetes in Experimental animals: 
The mechanism by which it induces diabetes is not very 
clear. Alloxan is a highly reactive molecule that is readily 
reduced to diuleric acid, which is then auto-oxidized back to 
alloxan resulting in the production of free radicals. These 
free radicals damage the DNA of B-cells and cause cell death. 
Second mechanism proposed for alloxan is its ability to react 
with protein SH groups, especially the membrane proteins 
like glucokinase on the B-cells, finally resulting in cell 
necrosis. However, there are major species differences in 
response to alloxan 7. 
General methodology to induce diabetes in 
Experimental animal: Rabbits weighing 2 to 3 kg are used. 
Alloxan is infused via the ear marginal vein at a dose of 150 
mg/kg for 10 minutes. About 70% animals become hyper 
glycemic and uricosuric. The remaining animals either die or 
are temporarily hyperglycemic. When rats of Wistar or 
Sprague-Dawley strain each weighing 150 to 200 g are used, 
alloxan is injected s.c. in the dose of 100-175 mg/ kg. In male 
Beagle dogs weighing 15 to 20 kg, alloxan is injected i.v.at a 
dose of 60 mg/ kg. Alloxan has been given to nonhuman 
primates like monkeys and baboons in the dose of 65-200 
mg/ kg i.v. to induce diabetes. All the animals, which are 
given alloxan, receive glucose and regular insulin for one 
week and food ad libitum. Thereafter, single daily dose of 28 
IU insulin is administered s.c .The blood glucose level shows 
triphasic change, first a rise at 2 h, followed by hypoglycemic 
phase at 8 h and finally an increase at 24 h probably due to 
depletion of B-cells of insulin 8. 
Modifications  
Diabetes can be induced in neonatal Sprague-Dawley rats by 
intraperitoneal injection of 200 mg/ kg alloxan on days 2, 4, 
or 6.  
Drawbacks - 
 High mortality in rats.  
 Causes ketosis in animals due to free fatty acid 
generation.  
 Diabetes induced is reversible.  
 Some species like guinea pigs are resistant to its 
diabetogenic action.   
 Alloxan has been almost completely replaced by 
Streptozotocin (STZ) for inducing diabetes because of 
these drawbacks. 
2. Streptozotocin- Induced Diabetes 
STZ (2-deoxy-2-(3-methyl-3-nitrosourea) l-D glucopyranose] 
is a broad-spectrum antibiotic, which is produced from 
Streptomyces achromogens. Rakieten et al first described the 
diabetogenic property of STZ 9. 
How Streptozotocin induce diabetes in animal: 
 By process of methylation  
 Free radical generation and  
 Nitric oxide production.  
General methodology to induce diabetes in animal: STZ 
induces diabetes in almost all species of animals. Diabeto 
genic dose varies with species and the optimal doses 
required in various species are: rats (50-60 mg/ kg, i.p. or 
i.v.), mice (175-200 mg/ kg i.p. or i.v.) and dogs (15 mg/ kg, 
for 3 days). The blood glucose level shows the same triphasic 
response as seen in the alloxan treated animals, with 
hyperglycemia at 1 h, followed by hypoglycemia, which lasts 
for 6 h, and stable hyperglycemia by 24-48 h after STZ 
administration 10.  
Modifications: 
Multiple low dose of STZ also induces diabetes by causing 
immune mediated pancreatic insulitis in rats. It has also been 
shown to have diabetogenic effect on the golden hamsters’. 
When given i.p at a dose of 50 mg/ kg. Cyclosporine-A when 
given with ST Z enhances its diabetogenic efficacy. STZ 
combined with complete Freund’s adjuvant: Each of CFA, 
incomplete Freund's adjuvant, Mycobacterium butyricum 
(component of CFA), Listeria monocytogenes, or endotoxin 
administered 24 h prior to STZ (25 mg/ kg) and then 
repeated on the three subsequent weeks all produce hyper 
glycemia. Fasting for 48 h (24 h prior to and 24 h subsequent 
to the STZ injection) also produces hyperglycemia. Neither 
four administration of CFA nor of STZ alone result in 
persistent hyperglycemia 11. 
STZ has almost completely replaced alloxan for inducing 
diabetes because of:  
 Greater selectivity towards B-cells  
 Lower mortality rate and  
 Longer or irreversible diabetes induction  
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 However, guinea pigs and rabbits are resistant to its 
diabetogenic action. 
3. Hormone-induced Diabetes Mellitus  
Dexamethasone, a long-acting glucocorticoid, is used to 
produce NIDDM. NIDDM form of diabetes is produced when 
dexamethasone is administered at a dose of 2-5 mg/ kg i.p. 
twice daily over a number of days in rats 12-15.  
4. Insulin Antibodies-induced Diabetes  
Giving bovine insulin along with CFA to guinea pigs produces 
anti-insulin antibodies. Intravenous injection of 0.25-1.0 ml 
guinea pig anti-insulin serum to rats induces a dose 
dependent increase in blood glucose levels up to 300 mg%. 
This unique effect to guinea pig anti- insulin serum is due to 
neutralization of endogenous insulin by the insulin 
antibodies. It persists as long as the antibodies are capable of 
reacting with insulin remaining in the circulation. Slow i.v 
.infusion or i.p. injection prolongs the effect for more than a 
few hours. However, large doses and prolonged 
administration are accompanied by ketonemia, ketonuria, 
glycosuria and acidosis and are fatal to the animals. After 
lower doses, the diabetic syndrome is reversible after a few 
hours 16. 
5. Diabetes induced by Viral Agents  
Viruses are thought to be one of the etiologic agents for 
IDDM; Viruses may produce diabetes mellitus by:  
 lnfecting and destroying of B-cells in pancreas,  
 A less infecting or cytologic variant producing a 
comparable damage by eliciting immune auto reactivity 
to the B-cells,  
 Viruses producing systemic effect, not directly affecting 
the B-cells.  
Various human viruses used for inducing diabetes include 
RNA picornoviruses, CoxsackieB4 (CB4), encephalo-
mylocarditis (EMC-D and M variants), Mengo-2T, as well as 
two other double stranded RNA viruses, reovirus and 
lymphocytic choriomeningitis virus (LMCV, Armstrong 
variant) (Table 1). Primary isolates of these human 
pathogenic agents are generally not pancreatotrophic or 
ilytic to mouse B-cells and must be adapted for growth either 
by inoculation into suckling mice or by passage in cultured 
mouse B-cells 17-18. 
                Table 1: susceptible mouse strain 17-18 
      Viruses   Susceptible mouse strain 
 
EMC-D or M variant 
Mengo-2T  
CB4 
Reo 
 
SJL/J ,SWR/J ,DBA/1J 
SJL ,C57BL/6L ,CBA/J 
SJL/J 
SJLj 
 
 
6. Surgically Induced Diabetes  
Induction of diabetes mellitus can be achieved through the 
surgical removal of all or part of the pancreas. In partial 
pancreatectomy more than 90% of the organ must be 
removed to produce diabetes. Depending on the amount of 
intact pancreatic cells, diabetes may range in duration from a 
few days to several months. Total removal of the pancreas 
results in an insulin-dependent form of diabetes, and insulin 
therapy is required to maintain experimental animals. The 
portion of the pancreas usually left intact following a 
subtotal pancreatic resection is typically the anterior lobe or 
a portion thereof.  
Disadvantages  
1. Surgical removal of pancreas results in loss of α and β-cells 
in addition to β-cells. This causes loss of counter-regulatory 
hormones, glucagon and somatostatin.  
2. There is a loss of the pancreatic enzymes necessary for 
proper digestion; therefore, the diet for pancreatectomised 
animals must be supplemented with these pancreatic 
enzymes.  
3. The total resection of the pancreas in rat is very difficult to 
achieve and the development and severity of the diabetic 
state appear to be strain specific.  
The use of pancreatectomy in combination with chemical 
agents, such as alloxan and STZ, produces a stable form of 
diabetes mellitus in animals, such as cats and dogs that does 
not occur when each procedure is applied independently. 
The combination therapy reduces the organ damage 
associated with chemical induction and minimizes the 
intervention, such as enzyme supplementation, necessary to 
maintain a pancreatectomised animal 19-20.  
Genetic Models  
1. The NOD Mouse  
Non-obese Diabetic (NOD) mice are an inbred strain of 
albino mice developed by Makino and co-workers, in Japan. 
It is derived from breeding JCL: ICR (Swiss mice) progenitors 
and NOD mice represent the product of over 80 generations 
of sib matings. Over the first 20 generations of sib matings, 
the strain was being maintained as a normoglycemic control 
line to match with another line being selected for impaired 
glucose tolerance (NON strain). Once spontaneous 
development of lDDM was observed in a female of the 
control NOD strain at F20, development of frank hyper-
glycemia and glycosuria rather than non-glycemia it became 
the selected phenotype 21. 
2. The BB Rat  
Spontaneous diabetes in the BB Wistar rat was initially 
diagnosed in 1974 by the Chapel brothers at the Biobreeding 
Laboratories commercial breeding facility in Ottawa, 
Ontario, Canada in a non inbred but closed outbred colony of 
Wistar rats. It was decided to name this syndrome BB after 
the initials of the breeding lab. The clinical presentation of 
diabetes or the BB rat is similar to that of its human 
counterpart. Marked hyperglycemia, glycosuria, and weight 
loss occur within a day of onset and are associated with 
decreased plasma insulin that if untreated will result in 
ketoacidosis within several days. Like the NOD mouse, the 
BB rat is one of the few rodent models in which significant 
ketosis occurs in the absence of obesity. Unlike most NOD 
mouse colonies, both sexes of BB rats are equally affected 22. 
MODELS FOR NIDDM  
 Chemically Induced Diabetes:  
1. Neonatal STZ Model of NIDDM 
Neonatal rats of Wistar or Sprague-Dawley strain are treated 
with STZ (80 to 100 mg/kg i.p.) at birth or within the first 5 
days following birth. There is severe pancreatic β-cell 
destruction, accompanied by a decrease in pancreatic insulin 
stores and a rise in plasma glucose levels. However, in 
contrast to adult rats treated with STZ, the B-cells of the 
treated neonates partially regenerate. Following an initial 
spike in plasma glucose the STZ heated neonatal rat becomes 
normoglycemic by 3 weeks of age. In the next few weeks, the 
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B-cell number increases mainly from the proliferation of 
cells derived from ducts, the extent, depending upon both 
the age at which the animal is treated with STZ and the 
species of the treated rat 23-24. 
 OTHER CHEMICALLY INDUCED NIDDM MODELS 
Agents used for induction of NIDDM in rabbits include 
adrenaline (0.1 mg/kg s.c.). The peak hyperglycemic effect is 
noticed at 1 h and lasts up to 4 h. The increase in blood sugar 
levels is found to be 120-150 mg/ 100 ml. Oral hypoglycemic 
agents can be screened by this method. Diabetes can also be 
induced in animals with chelating agent’s 8-hydroxy 
quinoline and biphenyl thiocarbazine. EDTA has been 
reported to be diabetogenic in partially depancreatized rats. 
Injection of an antiserum produced against ox insulin in 
guinea pigs or sheep causes diabetes in mice. Diabetes is 
associated with acute insulin deficiency and the animals 
exhibit marked hyperglycemia and ketonuria. It is, however, 
temporary in nature. This model does not have serious toxic 
side effects like other models, but induces mild pancreatitis 
in rats. Administration of thiazides, chlorthiazide, 
hydrochlorothiazide, diazoxide and furosemide produced 
hyperglycemia and glycosuria in experimental animals, 
including rabbits, rats and mice. Diazoxide is found to be 
effective either alone or in combination with other drugs 16.  
CONCLUSION 
Hyperglycemia is presumed to be a primary factor in the 
onset of diabetes, although hyperlipidemia also plays a role. 
The major organs active in the regulation of blood glucose 
are the pancreas, liver, skeletal muscle, adipose tissue, 
intestine, and kidney. In this overview, we laid emphasis 
upon number of experimental animal models used in 
diabetes research. It is important to emphasize that various 
experimental animal models are critical for developing new 
anti-diabetic drugs and explaining the activity of any agent 
before human clinical trials are to be conducted. With the 
advances in research, more therapeutic options will become 
available in the treatment of Diabetes Mellitus. These models 
explained help in the screening of the anti-diabetic activity of 
various promising molecules.  
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